Neurology Department, Corlu Military Hospital, Tekirdag, Turkey.
Diabetes Res Clin Pract. 2010 Dec;90(3):256-60. doi: 10.1016/j.diabres.2010.09.014. Epub 2010 Oct 12.
Nerve conduction studies (NCS) and Michigan Neuropathy Screening Instrument (MNSI) are commonly used to make the diagnosis of diabetic peripheral neuropathy. The objective of this study was to compare the diagnostic values of MNSI patient version test and physical test for the assessment of the diabetic peripheral neuropathy in obese vs. non-obese patients.
This study was conducted on 70 type 2 diabetic patients. We carried out the MNSI patient version test and MNSI physical assessment test. Nerve conduction studies were performed for the diagnosis of the diabetic peripheral neuropathy.
In diabetic peripheral neuropathy (DPN) determined by NCS, the independent prediction of peripheral neuropathy was the score of Michigan physical assessment (odds 2.0; CI: 1.3-3.0). In BMI (body mass index) ≥ 30 diabetic patients who have peripheral neuropathy, Michigan patient version test is not significant. But the score of Michigan physical assessment is significantly increased in these patients compared to patients without peripheral neuropathy. In BMI<30 diabetic patients who have peripheral neuropathy, scores of both Michigan patient version and physical assessment instruments are significantly increased.
To screen diabetic peripheral neuropathy, Michigan physical assessment may be more useful instrument than Michigan patient version test in obese diabetic patients.
神经传导研究（NCS）和密歇根神经病变筛查工具（MNSI）常用于诊断糖尿病周围神经病变。本研究旨在比较 MNSI 患者版测试和体格检查对肥胖和非肥胖患者糖尿病周围神经病变的评估的诊断价值。
本研究纳入 70 例 2 型糖尿病患者。我们进行了 MNSI 患者版测试和 MNSI 体格评估测试。神经传导研究用于诊断糖尿病周围神经病变。
在 NCS 确定的糖尿病周围神经病变（DPN）中，周围神经病变的独立预测因素是密歇根体格评估的评分（优势比 2.0；95%置信区间：1.3-3.0）。在 BMI（体重指数）≥30 的患有周围神经病变的糖尿病患者中，密歇根患者版测试不显著。但与无周围神经病变的患者相比，这些患者的密歇根体格评估评分显著增加。在 BMI<30 的患有周围神经病变的糖尿病患者中，密歇根患者版和体格评估工具的评分均显著增加。
对于筛查糖尿病周围神经病变，在肥胖的糖尿病患者中，密歇根体格评估可能比密歇根患者版测试更有用的工具。
